Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 13/20 | 0.54 |
| ▸ | CYP11B2 | P19099 | 13/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.45 |
| ▸ | LDHA | P00338 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25297947 | 0.85 | KMT2A (0.37) | CYP11B1CYP11B2FLT3NPC1RAB9A | |
| SCHEMBL6260766 | 0.79 | CYP11B1 (0.46) | CYP11B1CYP11B2NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1772141 | 0.79 | KIF11 (0.41) | CYP11B1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL31735530 | 0.78 | CYP11B1 (0.41) | CYP11B1CYP11B2FLT3LDHANPC1 | |
| SCHEMBL2717142 | 0.76 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4LDHAHPGDS | |
| SCHEMBL18291876 | 0.76 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4LDHAHPGDS | |
| SCHEMBL20122190 | 0.76 | CYP11B1 (0.80) | CYP11B1CYP11B2CYP3A4LDHAHPGDS | |
| SCHEMBL1720975 | 0.76 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4LDHAHPGDS | |
| SCHEMBL2412899 | 0.76 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4LDHAHPGDS | |
| SCHEMBL2411349 | 0.76 | CYP11B1 (0.59) | CYP11B1CYP11B2CYP3A4LDHAHPGDS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621925-B1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| EP-2621925-B1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME (US) | 2017-06-21 | — | — | EP | disclosed |
| US-8927562-B2 | Fused tricyclic inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927562-B2 | Fused tricyclic inhibitors of mammalian target of rapamycin | MERCK SHARP & DOHME CORP. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20130281474-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME CORP. (US) | 2013-10-24 | — | — | US | disclosed |
| US-20130281474-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MERCK SHARP & DOHME CORP. (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2621925-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| WO-2012047569-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047570-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047570-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-04-12 | — | — | WO | disclosed |
| WO-2012047569-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | SCHERING CORPORATION (US) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281474-A1 | FUSED TRICYCLIC INHIBITORS OF MAMMALIAN TARGET OF RAPAMYCIN | MTOR, RICTOR, RPTOR | CYP11B1 3865/4885CYP11B2 4118/4885CYP3A4 4621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.